Ken Griffin Roivant Sciences Ltd. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 138,700 shares of ROIV stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
138,700
Previous 97,500
42.26%
Holding current value
$1.6 Million
Previous $983,000
59.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ROIV
# of Institutions
361Shares Held
456MCall Options Held
8.34MPut Options Held
720K-
Sb Investment Advisers (Uk) LTD London, X060MShares$694 Million5.36% of portfolio
-
Morgan Stanley New York, NY44.7MShares$517 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.3MShares$455 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$409 Million0.01% of portfolio
-
Viking Global Investors LP34.2MShares$396 Million1.22% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.15B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...